Home › Compare › YMAIF vs ABBV
YMAIF yields 3571.43% · ABBV yields 3.06%● Live data
📍 YMAIF pulled ahead of the other in Year 1
Combined, YMAIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YMAIF + ABBV for your $10,000?
Yoma Strategic Holdings Ltd., an investment holding company, engages in the real estate, automotive and heavy equipment, consumer, financial, and investment businesses in Singapore, Myanmar, and the People's Republic of China. The company's Real Estate Development segment develops and sells land and properties. Its Real Estate Services segment provides project management, design, and estate management services, as well as property leasing services and operates golf estate. The company's Automotive & Heavy Equipment segment supplies and sells agriculture and construction equipment, passenger and commercial vehicles, and related parts, as well as offers maintenance services. Its Consumer segment engages in the operation of restaurants; bottling and distribution of beverages; food wholesale business; and provision of logistics services. The company's Financial Services segment provides vehicle financing; and invests in mobile financial services. Its Investments segment invests in the infrastructure, tourism, power agricultural, and other sectors, as well as leases investment properties. The company also engages in leasing automotive equipment. The company was formerly known as Sea View Hotel Limited. Yoma Strategic Holdings Ltd. was incorporated in 1962 and is based in Singapore.
Full YMAIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.